Moderna : ESCMID 2026 (mRNA-1010 Phase 3 sequential administration in adults 50+)

Published: 2026-04-21 13:56:10 ET MRNA

Published on 04/21/2026 at 01:56 pm EDT

Anita Kohli, Elissa Malkin, Ren Chen, Evelyn Du, Alicia Pucci, Rituparna Das, Eleanor Wilson

18 April 2026

Presented at the European Society of Clinical Microbiology and Infectious Diseases

Munich, Germany

Elissa Malkin, Ren Chen, Evelyn Du, Alicia Pucci, Rituparna Das, and Eleanor Wilson are employees of Moderna, Inc., and hold stock/stock options in the company. All relevant financial disclosures have been mitigated

Anita Kohli is an employee of The Institute for Liver Health Arizona and has no conflicts of interest to disclose

Medical writing and editorial assistance were provided by MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors

This study was funded by Moderna, Inc.

Additional Information

Please scan the QR code for a copy of the oral presentation and related conference materials

Copies of this oral presentation obtained through this QR code are for personal

use only and may not be reproduced without written permission of the authors

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: target product profile; efficacy and safety; and the potential for regulatory approval. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those described in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at https://www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments, or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

mRNA encoding for haemagglutinin (HA) glycoproteins

glycoproteins

Ribosome

Golgi

Encoded mRNAs

Endoplasmic

reticulum

Nucleus

mRNA-1010 encodes membrane-bound HA of

WHO-recommended seasonal influenza strains

Potential to address several limitations associated with currently licensed influenza vaccines1-4

Encodes specific antigen protein (precise match)

No requirement for egg-based or other complex culture systems

Reduced production time allowing for strain selection closer to start of influenza season and decreasing risk for mismatch

Elicited superior immunogenicity compared with licensed standard-dose

(in adults aged 18-64 years) and high-dose (in adults aged ≥65 years) licensed influenza vaccine comparators5

Demonstrated superior prevention of

RT-PCR-confirmed protocol-defined ILI in adults ≥50 years, without evident safety concerns6

HA, haemagglutinin; ILI, influenza-like illness; RT-PCR, reverse transcription polymerase chain reaction; WHO, World Health Organization.

1. World Health Organization. Wkly Epidemiol Rec. 2022;19:185-208. 2. Barr IG, et al. NPJ Vaccines. 2018;3:44. 3. Dolgin E. Nat Rev Drug Discov. 2021;20:801-803. 4.Okoli GN, et al. Vaccine. 2021;39:1225-1240. 5. Soens M, et al.

Vaccine. 2025;50:126874. 6. Malkin E, et al. Presented at: IDWeek 2025; October 19-22, 2025; Atlanta, GA.

Kohli A, Malkin E, Chen R, et al. Sequential administration of an mRNA-based seasonal influenza vaccine in older adults. Presented at: ESCMID Global 2026; 17-21 April 2026; Munich, Germany.

Study 304: Randomised, Double-Blind, Active-Controlled Phase 3 Trial (NCT06602024)

1:1

40,703 Adults ≥50 Yearsa

Randomised and

mRNA-1010 (37.5 μg TIV)

mRNA Seasonal Influenza Vaccine Candidate

Licensed SD Influenza Vaccine

(45 μg TIV or 60 μg QIV)

Licensed Inactivated SD

Received Study Vaccination (Safety Set)

Seasonal Influenza Vaccine

Followed through 6 months (Day 181) or end of influenza season, whichever occurred later

11 countries and 301 global sites

QIV, quadrivalent; SD, standard dose; TIV, trivalent.

Active comparators include Fluarix (TIV), Fluarix Tetra, Influsplit® Tetra, Alpharix® Tetra.

a47.8% of participants were ≥65 years old; 11.6% of participants were ≥75 years old.

Kohli A, et al. Sequential administration of an mRNA-based seasonal influenza vaccine in older adults. Presented at: ESCMID Global 2026; 17-21 April 2026; Munich, Germany.

Disclaimer

Moderna Inc. published this content on April 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 21, 2026 at 17:55 UTC.